Predicting lymph node metastasis in colorectal cancer patients: development and validation of a column chart model.

Lymph node metastasis (LNM) is one of the crucial factors in determining the optimal treatment approach for colorectal cancer. The objective of this study was to establish and validate a column chart for predicting LNM in colon cancer patients. We extracted a total of 83,430 cases of colon cancer from the Surveillance, Epidemiology, and End Results (SEER) database, spanning the years 2010-2017. These cases were divided into a training group and a testing group in a 7:3 ratio. An additional 8545 patients from the years 2018-2019 were used for external validation. Univariate and multivariate logistic regression models were employed in the training set to identify predictive factors. Models were developed using logistic regression, LASSO regression, ridge regression, and elastic net regression algorithms. Model performance was quantified by calculating the area under the ROC curve (AUC) and its corresponding 95% confidence interval. The results demonstrated that tumor location, grade, age, tumor size, T stage, race, and CEA were independent predictors of LNM in CRC patients. The logistic regression model yielded an AUC of 0.708 (0.7038-0.7122), outperforming ridge regression and achieving similar AUC values as LASSO regression and elastic net regression. Based on the logistic regression algorithm, we constructed a column chart for predicting LNM in CRC patients. Further subgroup analysis based on gender, age, and grade indicated that the logistic prediction model exhibited good adaptability across all subgroups. Our column chart displayed excellent predictive capability and serves as a useful tool for clinicians in predicting LNM in colorectal cancer patients.

N6-methyladenosine methylation analysis of long noncoding RNAs and mRNAs in 5-FU-resistant colon cancer cells.

N6 methyladenosine (m6A), methylation at the sixth N atom of adenosine, is the most common and abundant modification in mammalian mRNAs and non-coding RNAs. Increasing evidence shows that the alteration of m6A modification level could regulate tumour proliferation, metastasis, self-renewal, and immune infiltration by regulating the related expression of tumour genes. However, the role of m6A modification in colorectal cancer (CRC) drug resistance is unclear. Here, MeRIP-seq and RNA-seq techniques were utilized to obtain mRNA, lncRNA expression, and their methylation profiles in 5-Fluorouracil (5-FU)-resistant colon cancer HCT-15 cells and control cells. In addition, we performed detailed bioinformatics analysis as well as in vitro experiments of lncRNA to explore the function of lncRNA with differential m6A in CRC progression and drug resistance. In this study, we obtained the m6A methylomic landscape of CRC cells and resistance group cells by MeRIP-seq and RNA-seq. We identified 3698 differential m6A peaks, of which 2224 were hypermethylated, and 1474 were hypomethylated. Among the lncRNAs, 60 were hypermethylated, and 38 were hypomethylated. GO and KEGG analysis annotations showed significant enrichment of endocytosis and MAPK signalling pathways. Moreover, knockdown of lncRNA ADIRF-AS1 and AL139035.1 promoted CRC proliferation and invasive metastasis in vitro. lncRNA- mRNA network showed that ADIRF-AS1 and AL139035.1 May play a key role in regulating drug resistance formation. We provide the first m6A methylation profile in 5-FU resistance CRC cells and analyse the functions of differential m6A-modified mRNAs and lncRNAs. Our results indicated that differential m6A RNAs were significantly associated with MAPK signalling and endocytosis after induction of 5-FU resistance. Knockdown of LncRNA ADIRF-AS1 and AL139035.1 promotes CRC progression and might be critical in regulating drug resistance formation.

We outline the first m6A methylation profile of mRNA and lncRNA in CRC cells involved in 5-FU resistance.This study sought to identify the critical genes that produced 5-FU resistance by analysing the functions of differentially m6A-modified mRNAs and lncRNAs.

Preoperative radiotherapy does not improve and may even be detrimental to the long-term prognosis of patients diagnosed with stage III colon adenocarcinoma: a propensity score-matched SEER database analysis.

Background: Currently, for patients with colon adenocarcinoma who are diagnosed with local lymph node metastasis, it is typically recommended to undergo neoadjuvant treatment before undergoing curative surgical intervention. Nowadays, the focus of preoperative adjuvant therapy for colon adenocarcinoma patients mainly revolves around chemotherapy, and the impact of preoperative radiotherapy on long-term prognosis remains uncertain. Methods: We extracted data from the Surveillance, Epidemiology, and End Results database for patients with stage III colon adenocarcinoma between 2004 and 2019. Using propensity score matching (PSM), the patients were divided into a preoperative radiotherapy group and a non-preoperative radiotherapy group, and the differences in Kaplan-Meier (KM) survival curves between the two groups were compared. Cox regression analysis was employed to identify clinical factors that influence survival in stage III colon adenocarcinoma, and the prognostic differences between the two groups were compared within specific subgroups of these clinical factors. Results: After PSM, a total of 242 patients were included in the study, divided into the preoperative radiotherapy group and the non-preoperative radiotherapy group. There were no statistically significant differences in important clinical characteristics between the two groups. KM analysis revealed no statistically significant difference in overall survival (OS) between the two groups. Furthermore, age, chemotherapy, T staging, N staging, race, tumor grade, gender, tumor location, and tumor diameter were identified as important factors influencing the prognosis of patients. Within each level of the aforementioned subgroups, there were no differences in OS between the two groups. In fact, in specific subgroups, the non-preoperative radiotherapy group exhibited better OS than the preoperative radiotherapy group. Conclusion: Preoperative radiotherapy does not improve the long-term prognosis of patients with stage III colon adenocarcinoma. In certain patient populations with specific clinical characteristics, preoperative radiotherapy may even lead to a decrease in OS.

Leveraging natural cognitive systems in conjunction with ResNet50-BiGRU model and attention mechanism for enhanced medical image analysis and sports injury prediction.

Introduction: In this study, we explore the potential benefits of integrating natural cognitive systems (medical professionals' expertise) and artificial cognitive systems (deep learning models) in the realms of medical image analysis and sports injury prediction. We focus on analyzing medical images of athletes to gain valuable insights into their health status. Methods: To synergize the strengths of both natural and artificial cognitive systems, we employ the ResNet50-BiGRU model and introduce an attention mechanism. Our goal is to enhance the performance of medical image feature extraction and motion injury prediction. This integrated approach aims to achieve precise identification of anomalies in medical images, particularly related to muscle or bone damage. Results: We evaluate the effectiveness of our method on four medical image datasets, specifically pertaining to skeletal and muscle injuries. We use performance indicators such as Peak Signal-to-Noise Ratio and Structural Similarity Index, confirming the robustness of our approach in sports injury analysis. Discussion: Our research contributes significantly by providing an effective deep learning-driven method that harnesses both natural and artificial cognitive systems. By combining human expertise with advanced machine learning techniques, we offer a comprehensive understanding of athletes' health status. This approach holds potential implications for enhancing sports injury prevention, improving diagnostic accuracy, and tailoring personalized treatment plans for athletes, ultimately promoting better overall health and performance outcomes. Despite advancements in medical image analysis and sports injury prediction, existing systems often struggle to identify subtle anomalies and provide precise injury risk assessments, underscoring the necessity of a more integrated and comprehensive approach.

Experimental and simulation study on aluminium alloy piston based on thermal barrier coating.

Thermal barrier coatings (TBCs) have low thermal conductivity, effectively reducing the temperature of the metal matrix and improving thermal performance, knock resistance, and combustion performance of the piston. In this study, an off-road high-pressure common-rail diesel engine was chosen as the research object. Combined with the test results of the piston temperature field under the rated power and maximum torque conditions, a finite element simulation model of the thermal barrier coating piston was established. This model enabled the distribution characteristics and variation laws of the temperature field, stress, and deformation of the thermal barrier coating on the piston matrix to be analysed. The results show that the maximum temperature of the TBC piston is 12.2% and 13.73% lower than that of the aluminium alloy piston under the rated power and maximum torque conditions, respectively. The thermal stresses of the TBC piston at the top of the cavity were 25.9% and 26.8% lower than those of the aluminium piston, while the thermo-mechanical coupling stress of the TBC piston was slightly higher than that of the aluminium piston-1.2 MPa and 3.7 MPa in the bottom of the combustion chamber with geometric mutation, respectively. The radial thermal deformation of the TBC piston was 0.067 mm and 0.073 mm lower than that of the aluminium piston, with the radial thermo-mechanical coupling deformation also decreasing by 0.069 mm and 0.075 mm, respectively. The radial thermal deformation of the piston in the direction parallel to the pinhole axis was greater than that in the direction perpendicular to the pinhole axis; the difference in the magnitude of the change results in uneven thermal deformation of the piston.

RNF2 promotes the progression of colon cancer by regulating ubiquitination and degradation of IRF4.

Ring finger protein 2 (RNF2), as a well-known E3 ligase, has an oncogenic role in various cancers. The role of RNF2 in colon cancer is still unknown. The aim of this work is to determine the biological role of RNF2 in colon cancer. We first examined the expression of RNF2 and interferon regulatory factor 4 (IRF4) in colon cancer patients and colon cancer cell lines (SW480 and HCT116). Compared with normal tumor-adjacent tissues, RNF2 was up-regulated whereas IRF4 was down-regulated in the colon cancer tissues. RNF2 was also up-regulated in colon cancer cells with respect to human fetal colon epithelial cells. RNF2 overexpression enhanced the ability of proliferation, migration and invasion of SW480 cells, whereas RNF2 knockdown caused an opposite result in HCT116 cells. Furthermore, a tumor xenograft model was constructed to verify the impact of RNF2 overexpressed-SW480 cells on tumor growth. RNF2 up-regulation elevated Ki-67 proliferation index, accelerated the growth of tumor tissues, and led to severe colon tissue damage in the tumor xenograft mice. In addition, RNF2 interacted with IRF4, and repressed IRF4 protein expression. IRF4 was a substrate of RNF2, and RNF2 promoted the ubiquitination and degradation of IRF4. RNF2 overexpression increased the ability of proliferation, migration and invasion in SW480 cells by promoting the ubiquitination and degradation of IRF4. In conclusion, this work demonstrated that RNF2 promoted tumor growth in colon cancer by regulating ubiquitination and degradation of IRF4. Thus, RNF2 may be served as a potential therapeutic target for colon cancer.

Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride.

Reaction of di-n-butyltin(IV) dichloride with 4-chlorobenzohydroxamic acid at 1:1 ratio yielded a new mixed-ligand diorganotin(IV) complex, di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride(DBDCT). It was fully characterized by IR, (1)H, (13)C, (119)Sn NMR spectra and single crystal X-ray analysis. In DBDCT, the tin atom is five-coordinated in a trigonal bipyramidal geometry. DBDCT exhibited strong in vitro cytotoxic activity toward human immature granulocyte leukemia (HL-60), human salivary-gland carcinoma (SGC-7901), human henrietta carcinoma (Hela) and human urinary bladder (T24) cell lines which, in some cases, were equal to, or even higher than those of cis-dichlorodiammineplatinum(II) (cisplatin, DDP), the widely clinically used drug. The further in vivo antitumor tests of DBDCT towards the transplantation tumor models of sarcoma carcinoma (S(180)), hepatocellular carcinoma (H(22)) and Ehrlich's ascites carcinoma (EAC) on mice were carried out via injection intraperitoneally with cisplatin as positive contrast drug. The results showed that DBDCT displayed in vivo antitumor activity against the hepatocellular carcinoma H(22) and sarcoma carcinoma S(180) which were close to those of cisplatin, meanwhile, the survival-extending rates at middle dose and high dose on mice Ehrlich's ascites tumor EAC were higher than those of cisplatin, and there was a good dose-effect relationship.